Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Int J Radiat Oncol Biol Phys. 2020 Nov 1;108(3):597-601. doi: 10.1016/j.ijrobp.2020.05.042. Epub 2020 Jun 1.
Many patients with lung cancer are inactive due to their disease and underlying comorbidities, and activity levels can decline further during cancer therapy. Here we explore dosimetric predictors of activity decline in a cohort of patients who underwent continuous activity monitoring during definitive concurrent chemoradiotherapy (CRT) for locally advanced lung cancer.
We identified patients who participated in prospective clinical trials involving the use of a commercial fitness tracker throughout the course of CRT. For each patient, we applied linear regression to log-transformed daily step counts to compute the weekly rate of activity change from 1 week before radiation therapy (RT) initiation to 2 weeks after RT completion. Clinical and dosimetric factors were tested as predictors of activity change using linear regressions.
Forty-six patient met the eligibility criteria. Median age was 66 years (range, 38-90). Pretreatment Eastern Cooperative Oncology Group performance status was 0, 1, and 2 for 17%, 70%, and 13%, respectively. Mean lung dose ranged from 5.0 to 23.5 Gy, mean esophagus dose from 1.1 to 39.6 Gy, and mean heart dose from 0.6 to 31.5 Gy. Median daily step count average was 5861 (interquartile range, 3540-8282) before RT and 3422 (interquartile range, 2364-5395) 2 weeks after RT completion. Rate of activity change was not significantly associated with age, performance status, or mean RT dose received by lungs or esophagus. In multivariate analysis, mean heart dose was significantly associated with rate of activity decline, with a 3.1% reduction in step count per week for every 10 Gy increase in mean heart dose (95% confidence interval: 0.5-5.7, P = .023).
Extent of cardiac irradiation is associated with the rate of physical activity decline during CRT for lung cancer. Our novel finding contributes to the growing body of evidence that adverse effects of cardiac irradiation may be manifested at early time points.
许多肺癌患者由于疾病和潜在合并症而活动能力下降,并且在癌症治疗过程中活动水平可能进一步下降。在这里,我们探索了在接受局部晚期肺癌根治性同期放化疗(CRT)的患者队列中,剂量学预测因子与活动能力下降的关系。
我们确定了参与涉及在 CRT 期间使用商业健身追踪器的前瞻性临床试验的患者。对于每个患者,我们应用线性回归对数变换后的每日步数,计算从放射治疗(RT)开始前 1 周到 RT 完成后 2 周的每周活动变化率。使用线性回归测试临床和剂量学因素作为活动变化的预测因子。
46 名患者符合入选标准。中位年龄为 66 岁(范围,38-90 岁)。治疗前东部合作肿瘤学组表现状态为 0、1 和 2,分别占 17%、70%和 13%。平均肺剂量范围为 5.0-23.5 Gy,平均食管剂量为 1.1-39.6 Gy,平均心脏剂量为 0.6-31.5 Gy。RT 前平均每日步数中位数为 5861(四分位距,3540-8282),RT 完成后 2 周为 3422(四分位距,2364-5395)。活动变化率与年龄、表现状态或肺或食管接受的平均 RT 剂量均无显著相关性。在多变量分析中,平均心脏剂量与活动下降率显著相关,平均心脏剂量每增加 10 Gy,每周步数减少 3.1%(95%置信区间:0.5-5.7,P =.023)。
心脏照射量与肺癌 CRT 期间的身体活动能力下降有关。我们的新发现为越来越多的证据表明,心脏照射的不良反应可能在早期表现出来做出了贡献。